2021 Fiscal Year Final Research Report
Translational research to elucidate the mechanism of diabetes- and obesity-related hepatocarcinogenesis
Project/Area Number |
19K23908
|
Research Category |
Grant-in-Aid for Research Activity Start-up
|
Allocation Type | Multi-year Fund |
Review Section |
0901:Oncology and related fields
|
Research Institution | Tokyo Medical and Dental University |
Principal Investigator |
Akahoshi Keiichi 東京医科歯科大学, 医学部附属病院, 助教 (80749523)
|
Project Period (FY) |
2019-08-30 – 2022-03-31
|
Keywords | 肝細胞癌 / チロシンキナーゼ阻害剤 / 進行肝癌 |
Outline of Final Research Achievements |
The proportion of hepatocellular carcinoma related to metabolic syndrome, such as diabetes and obesity, is increasing. These hepatocellular carcinomas were often found in relatively advanced stages. We analyzed the efficacy of a combination of lenvatinib, a novel therapeutic agent, and surgery for the treatment of advanced liver cancer. Lenvatinib treatment was effective within 1-2 months, and tumor markers correlated with treatment response. The proportion of patients who were successfully treated with lenvatinib and surgery was approximately 50%, and those who were operated on had a significantly better prognosis, suggesting that the combination of lenvatinib and surgery is an effective new treatment strategy that can be safely administered to patients with advanced liver cancer. In addition, a comprehensive genetic analysis of surgically resected cases revealed eight genes that correlate with the efficacy of drug therapy, which may lead to further research.
|
Free Research Field |
肝胆膵外科
|
Academic Significance and Societal Importance of the Research Achievements |
近年肝癌薬物療法が急速に進歩して新時代を迎えている。従来は手術不能な症例が手術可能となることは非常にまれであったが、本研究で用いたレンバチニブは約50%と非常に高率で手術治療を加えることが可能であった。そして薬物療法後の手術であっても手術後の回復経過に違いはなく、薬物療法と手術の組み合わせ治療の安全性と有効性が示された。 さらに薬物療法の効果とを予測するバイオマーカー候補となる遺伝子が見いだされ、肝癌治療の進歩に寄与できると考えられ、さらなる研究の継続が求められている。
|